Peter Schulam, MD, PhD

Peter Schulam, MD, PhD

Yale School of Medicine

New Haven, Connecticut

Dr. Peter Schulam graduated from the Medical Scientist Training Program at Baylor College of Medicine with an MD and a PhD in Immunology and completed his surgical and urologic training at Johns Hopkins Hospital in Baltimore, Maryland. Following a brief period at Baylor in Houston, he was recruited as the Chief of Minimally Invasive Surgery in the Department of Urology at UCLA. At UCLA, he developed laparoscopic and robotic surgery programs for prostate and kidney cancer. Dr. Schulam was also the Surgical Director of the Living Kidney Donor Program and performed over 1,200 laparoscopic living donor kidney procedures. At UCLA, he became the vice chair of the department and was actively involved in improving the patient experience throughout the hospital. In January of 2012, he became the Chair of the Department of Urology at Yale. Dr. Schulam's focus is to build a program that can offer every patient with any urologic condition state of the art diagnosis and treatment in an environment that is patient centered and is committed to listening and engaging the patient in their care.

Articles by Peter Schulam, MD, PhD

Technology and its Impact on Patient Care

Peter Schulam, MD, PhD, argues that adopting robotic assisted surgery into urological practices can reduce medical errors and surgeon performance variability. Furthermore, he explains the need for larger and more structured medical data sets. This will enable machine learning when developing artificial intelligence (AI) to enhance prognostic and diagnostic accuracy, cancer mortality prediction, and interpretation of digitized images.

Read More

Surgical Management of Stone Disease

Peter Schulam MD, PhD, discusses the 2016 American Urological Association (AUA)/ Endourology Society guidelines regarding observation of renal calculi, the treatment of ureteral and renal stones, urolithiasis during pregnancy, and the role of open surgery in stone disease. Specifically, he discusses medical expulsive therapy (MET), ureteroscopy, and shockwave lithotripsy (SWL).

Read More

MRI Fusion Biopsy

Peter Schulam, MD, PhD, reviews the controversy surrounding prostate cancer screening, explains the literature that led to the United States Preventive Services Task Force (USPSTF) coming out with a C recommendation for prostate cancer screening, and notes the limitations in the current standard of transrectal ultrasound (TRUS) biopsy. He then discusses how MRI fusion biopsy could address these limitations.

Read More

Adverse Pathologic Characteristics in the Small Renal Mass

Peter Schulam MD, PhD, emphasizes the importance of staging renal tumors based on weighted risk, including risk of metastases, histologic subtypes, and adverse pathologic characteristics, and not simply mass size. This is essential when considering partial nephrectomy, radical nephrectomy, active surveillance, ablative techniques, or other management options for individual patients.  

Read More

Join the GRU Community

- Why Join? -